BMO Capital Markets reiterated their buy rating on shares of Edwards Lifesciences Corporation (NYSE:EW) in a research note published on Friday, September 1st. BMO Capital Markets currently has a $132.00 price target on the medical research company’s stock.
EW has been the subject of several other research reports. BidaskClub downgraded shares of Edwards Lifesciences Corporation from a strong-buy rating to a buy rating in a report on Tuesday, June 13th. Canaccord Genuity reaffirmed a buy rating and issued a $150.00 price objective on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a hold rating to a buy rating and set a $129.00 price target for the company in a report on Thursday, June 1st. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Edwards Lifesciences Corporation in a report on Tuesday, May 16th. They issued a conviction-buy rating and a $138.00 price target for the company. Finally, Cowen and Company reissued an outperform rating and issued a $135.00 price target (up from $130.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $120.75.
Edwards Lifesciences Corporation (NYSE EW) opened at 113.50 on Friday. The stock has a market capitalization of $23.97 billion, a price-to-earnings ratio of 34.43 and a beta of 0.64. The company’s 50-day moving average is $113.99 and its 200 day moving average is $108.88. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75.
Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.20. The company had revenue of $842.00 million during the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.76 earnings per share. Equities analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.
In related news, VP Donald E. Bobo, Jr. sold 5,600 shares of the firm’s stock in a transaction dated Thursday, June 29th. The stock was sold at an average price of $117.15, for a total value of $656,040.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $114.80, for a total value of $3,776,920.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 163,541 shares of company stock valued at $18,712,719. 2.13% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. ETF Managers Group LLC bought a new position in Edwards Lifesciences Corporation during the second quarter worth about $112,000. YorkBridge Wealth Partners LLC bought a new position in Edwards Lifesciences Corporation during the first quarter worth about $110,000. NEXT Financial Group Inc raised its position in shares of Edwards Lifesciences Corporation by 91.7% during the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock worth $115,000 after purchasing an additional 500 shares during the period. Shine Investment Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences Corporation during the second quarter worth about $126,000. Finally, Cornerstone Advisors Inc. raised its position in shares of Edwards Lifesciences Corporation by 25.1% during the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after purchasing an additional 219 shares during the period. Hedge funds and other institutional investors own 82.36% of the company’s stock.
Edwards Lifesciences Corporation Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.